One Shot to Rule Them All: Europe's Bet on a Flu-COVID Combo Vaccine
Europe just approved the world's first vaccine combining flu and COVID protection in a single shot. Moderna's mCOMBRIAX beat the best standalone vaccines in clinical trials, and it arrives at a moment when COVID booster uptake among older Europeans has cratered to under 9%.
Every autumn, tens of millions of Europeans over 50 face the same ritual. Roll up one sleeve for the flu shot. Roll up the other for a COVID booster. Schedule two appointments, deal with two rounds of side effects, and hope you actually show up for both. It's the vaccination equivalent of needing two separate remotes to watch TV.
As of this week, Europe just got a universal remote.
The First of Its Kind
The European Commission granted marketing authorization to mCOMBRIAX, Moderna's combined influenza and COVID-19 vaccine, for adults aged 50 and older. It's approved across all 27 EU member states plus Iceland, Liechtenstein, and Norway. One dose. Two viruses. No sequel needed.
This isn't just a regulatory checkbox. It's the first vaccine ever approved that protects against both seasonal flu and COVID-19 in a single shot. The approval is based on a Phase 3 trial of roughly 8,000 adults, split into two age groups: 50 to 64, and 65 and up. In both cohorts, the combo vaccine didn't just match existing standalone shots. It beat them.
Better Than the Sum of Its Parts
The trial compared mCOMBRIAX against the best available options given together: a licensed flu vaccine plus Moderna's own COVID vaccine, Spikevax. For older adults (65+), the flu comparator was Sanofi's Fluzone High-Dose, which is the gold standard for seniors. That's a high bar.
mCOMBRIAX cleared it. Against three of the most clinically relevant flu strains (A/H1N1, A/H3N2, and B/Victoria), the combo shot triggered statistically higher antibody responses than Fluzone High-Dose. For COVID, the advantage was even more striking: antibody levels were significantly higher than those from a standalone Spikevax dose.
Think of it like upgrading from two decent speakers to a single soundbar that somehow sounds better than both combined. One product, superior performance.
The immune responses also proved durable, lasting at least six months after a single dose. That's the length of a typical respiratory virus season, which is exactly what you'd want from an annual shot.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
The Safety Question
Naturally, stuffing two vaccines into one syringe raises eyebrows. The trial data, though, was reassuring. Side effects were slightly more common with the combo (83.5% of seniors reported some reaction, versus 78.1% for the two separate shots), but the vast majority were mild: sore arms, fatigue, headaches. The usual suspects. No serious safety signals emerged, and follow-up data through six months showed no vaccine-related deaths or unexpected problems.
In short, you feel a little crummier for a day or two. That's the trade-off for skipping an entire extra appointment.
Why Europe Desperately Needs This
Here's the number that should make public health officials lose sleep: COVID-19 booster uptake among Europeans aged 60 and older hit just 8.7% in the 2024–2025 season. For context, flu coverage among older Europeans was only 45.7%, and that's considered disappointing. COVID boosters are in the basement.
The reasons are predictable. Vaccination fatigue. Scheduling hassles. A general sense that the pandemic is "over." When you ask people to make two separate trips to a clinic for two separate shots, a lot of them make zero trips instead.
A combo vaccine attacks this problem at the root. One appointment, one needle, full protection. Surveys suggest about 60% of consumers prefer a single all-in-one shot when given the option. Removing friction saves lives; it's that simple.
The Race Moderna Is Winning (for Now)
Being first matters in vaccines. It sets the reference point for health systems, shapes procurement decisions, and builds brand loyalty with doctors and patients. Right now, Moderna has the field to itself in combo flu-COVID vaccines. But the rearview mirror isn't empty.
Pfizer and BioNTech have their own mRNA combo in Phase 3, though it stumbled when it failed to demonstrate adequate effectiveness against influenza B in a key trial readout. That setback makes Pfizer a second-wave entrant at best, needing reformulated data before it can catch up.
Novavax is taking a different approach entirely, developing a protein-based combo vaccine with its Matrix-M adjuvant. Phase 3 immune response data from mid-2025 looked promising in adults 65 and older, with results intended to inform a forthcoming registrational trial and regulatory discussions. Novavax is also licensing its adjuvant technology to both Sanofi and Pfizer, positioning itself as the "Intel Inside" of the vaccine world.
The competitive picture is clear: Moderna leads, Novavax is building momentum through partnerships, and Pfizer is regrouping.
The Elephant in the Room: America
For all the celebration in Brussels, Moderna's combo shot still doesn't have a path to U.S. approval. The FDA's process has been, to put it diplomatically, complicated. The agency wants standalone flu efficacy data before greenlighting the combo, and Moderna's flu-only candidate (mRNA-1010) isn't yet approved anywhere. Moderna's CFO Jamey Mock explicitly told investors that the company's 2026 forecast assumes zero revenue from the combo vaccine.
William Blair analysts noted they were "surprised at the willingness of the EC to grant approval" given that the flu component isn't independently authorized in Europe either. The EMA, it seems, was willing to evaluate the combo on its own merits. The FDA, so far, is not.
This creates an unusual dynamic. Moderna's most innovative product will generate revenue in Europe, Canada, and potentially other markets long before it ever reaches American arms. For a company that built its empire on U.S. pandemic contracts, that's a meaningful strategic shift.
What This Really Means
mCOMBRIAX is Moderna's fourth authorized product in Europe, joining its COVID vaccine, its updated COVID booster (mNEXSPIKE), and its RSV vaccine (mRESVIA). The company is no longer a one-trick pony. It's building a respiratory vaccine portfolio, with a standalone flu vaccine also under review in the EU and early-stage work on flu-plus-RSV and even triple combos (flu, COVID, and RSV) in clinical testing.
The mRNA platform, initially proven in a crisis, is now being used like a modular toolkit: snap different viral targets together, run them through the same manufacturing process, and create products that are genuinely more convenient for patients. It's the Swiss Army knife argument, and the EU just validated it.
For the millions of older Europeans who skip their boosters every year, this approval could be the nudge that changes behavior. One shot, one visit, two viruses handled. It won't fix vaccine hesitancy overnight. But it removes one of the biggest excuses people have for not showing up.
And in public health, removing excuses is half the battle.
Clinical & Regulatory
4 min read
The FDA Fired Thousands of People. Now It's Hiring 2,200 Back.
The FDA slashed 3,000 workers last year. Now it's scrambling to hire 2,200 back, but the math still doesn't add up. Here's what it means for drug approvals, biotech timelines, and whether the regulatory engine can survive the whiplash.
